- Home
- PRZO vs PPBT Comparison
PRZO vs PPBT Comparison
Compare PRZO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | PPBT |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 2.4M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PRZO | PPBT |
|---|---|---|
| Price | $0.68 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 2.7M | 2.1M |
| Earning Date | 03-26-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.41 |
| 52 Week High | $1.90 | $5.18 |
Technical Indicators
Market Signals| Indicator | PRZO | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 37.27 |
| Support Level | $0.66 | $1.35 |
| Resistance Level | $0.82 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 16.05 | 6.97 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.